ALT Great stories deserve to be read. Market Pathways is offering qualifying #medtech companies a FREE feature article to help showcase their innovation and increase industry visibility. Get it here: https://bit.ly/4v1QSxg

ALT The #medtech landscape moves fast. Stay a step ahead. Get expert insights on policy, regulation, #FDA updates, and market access with the Market Pathways newsletter: https://bit.ly/4g67v67

ALT The #medtech journey is complex. The right resources make all the difference. Explore the Market Pathways Toolkit for expert insights on regulation, #reimbursement, and commercialization: https://bit.ly/4v4MWfg

ALT A major reversal is taking shape in Europe’s #medtech regulatory system. EU notified body staffing fell nearly 13% in 2025 as MDR/IVDR submissions slowed and manufacturers await #regulatory reforms: https://bit.ly/4xeBzma

ALT Market access is moving faster than ever. Stay ahead of #regulatory, reimbursement, and policy changes shaping global #medtech with insights from Market Pathways: https://bit.ly/4dSb3pT

ALT Australia remains a market to watch for #medtech. 95% of devices gain TGA registration through abridged pathways, while major safety and #reimbursement changes continue to reshape the landscape: https://bit.ly/4olzEZj

ALT Generative #AI may need a medical license, not a device clearance. A new proposal suggests regulating autonomous #healthcare AI more like physicians, with exams, supervised training, and ongoing oversight: https://bit.ly/4nYI7Be

ALT Stop digging through dozens of #regulatory websites. Pathways Document Depot puts global #medtech policy, guidance, reports, and regulatory documents in one searchable database: https://bit.ly/43LL7re

ALT The 3FDA got off to a strong start in 2026. Q1 saw the highest number of novel #medtech device approvals since at least 2019, with continued growth in 510(k) clearances and PMA supplements.

ALT Keeping up with #medtech policy and reimbursement changes can feel like a full-time job. The Market Pathways Podcast makes it easier with real conversations and practical insights from industry experts. Get access here: https://bit.ly/4uD61VA

ALT #FDA approval is only part of the challenge. Coverage is the other half of the equation. “If it's successful, you get your FDA approval, you get coverage.” Big discussion around RAPID at #InnovationDublin: https://bit.ly/3PqfDnl

ALT Struggling with #MDR/IVDR classification? The updated EU Borderline & Classification Manual (v5, April 2026) offers key guidance. Explore it and access more in Pathways’ Document Depot: https://bit.ly/4dZDRyB

ALT The shift is here, and many aren’t ready. Regulators are now analyzing device safety data and expect manufacturers to do the same. Why 2026 is a turning point for surveillance: https://bit.ly/4euIj8F #medtech

ALT Faster coverage is the goal, but questions remain. @FDADeviceInfo and @CMSGov introduce RAPID to align approval and #Medicare coverage for Breakthrough Devices. Industry is watching closely as details unfold: https://bit.ly/4d8cvEp #medtech

ALT Postmarket surveillance is evolving fast. Regulators now expect manufacturers to actively analyze device safety data, not just submit it. Read more here: https://bit.ly/4doCmYV #medtech

ALT The conversations shaping #medtech are happening here. Get access to the Market Pathways Podcast for insights on global regulation, #reimbursement, policy, and market access: https://bit.ly/3PhZEaz

ALT Policy shifts shape #medtech long before headlines do. Market Pathways delivers the regulatory, reimbursement, and #policy insight professionals use to stay ahead. Learn more here: https://bit.ly/4dLr3Lz

ALT The #FDA approval pathway is evolving. At #InnovationDublin 2026, @joshatstanford and Steve Farmer debated whether pivotal trials can also meet Medicare coverage standards. A major conversation for #medtech market access: https://bit.ly/495PNLQ